| Code | CSB-RA023977MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Atrosimab, designed for research targeting TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily Member 1A), also known as TNFR1 or CD120a. TNFRSF1A is a cell surface receptor that binds TNF-alpha and plays a crucial role in mediating inflammatory responses, immune regulation, and apoptotic signaling pathways. Upon TNF-alpha binding, TNFRSF1A activates multiple downstream signaling cascades including NF-κB and MAPK pathways, which are central to inflammation and cell survival. Dysregulation of TNFRSF1A signaling is implicated in various autoimmune disorders, chronic inflammatory diseases, sepsis, and certain malignancies.
Atrosimab represents an investigational therapeutic antibody developed to modulate TNFRSF1A activity and TNF-alpha-mediated inflammatory responses. This biosimilar provides researchers with a valuable tool for investigating TNF receptor biology, inflammatory signaling mechanisms, and potential therapeutic interventions in immune-mediated diseases. It supports studies exploring receptor-ligand interactions, signal transduction pathways, and the pathophysiology of TNF-related disorders in various experimental models.
There are currently no reviews for this product.